ReviewFrontiers in medicine2022
ImmunoPET: Antibody-Based PET Imaging in Solid Tumors.
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 52 citations in OpenAlex.
- scFv-Fcs as a Radiotheranostic Platform for Targeting TRA-1-60 in Pancreatic Cancers.Research square · 2026Article
- scFv-Fcs as a Radiotheranostic Platform for Targeting TRA-1-60 in Pancreatic Cancers.Research square · 2026Article
- Specific PET Imaging for Precision Management of Lung Cancer: Advances, Clinical Translation and Future Directions.Chemical & biomedical imaging · 2026Review
- Tetraspanin-8 as a Tumor-Selective Immuno-PET Target in Hepatocellular Carcinoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Biodistribution, dosimetry, and preliminary imaging of the novel Nectin-4-targeting PET tracer [⁶⁸Ga]Ga-FZ-NR-1 in humans.EJNMMI research · 2026Article
- Anti-cancer immune priming with β-radioligand therapy using a novel high affinity antibody selectively targeting the 4Ig-Isoform of B7-H3.Theranostics · 2026Article
- A high-affinity CEA-targeted nanobody forJournal of nanobiotechnology · 2025Article
- Article
- Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies.Pharmaceutics · 2025Article
- Imaging PD-L1 in the brain-Journey from the lab to the clinic.Neuro-oncology · 2025Article
- A Highly Sensitive Immunoassay to Enable Quantification of a Nanobody-Based Imaging Agent in Human Serum.The AAPS journal · 2025Article
- Molecular Imaging of Tumor-Infiltrating Lymphocytes in Living Animals Using a Novel mCD3 Fibronectin Scaffold.Bioconjugate chemistry · 2025Article
- Ultra-low dose immunoPET usingFrontiers in medicine · 2025Article
- Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook.Molecular pharmaceutics · 2024Review
- Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes?Cell communication and signaling : CCS · 2024Review
- Radiopharmaceuticals for Pancreatic Cancer: A Review of Current Approaches and Future Directions.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Development ofMolecular imaging and biology · 2024Article
- Radioimmunotheragnosis in Cancer Research.Cancers · 2024Review
- Engineered Antibodies as Cancer Radiotheranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immuno-positron emission tomography (immunoPET) is a molecular imaging modality combining the high sensitivity of PET with the specific targeting ability of monoclonal antibodies. Various radioimmunotracers have been successfully developed to target a broad spectrum of molecules expressed by malignant cells or tumor microenvironments. Only a few are translated into clinical studies and barely into clinical practices. Some drawbacks include slow radioimmunotracer kinetics, high physiologic uptake in lymphoid organs, and heterogeneous activity in tumoral lesions. Measures are taken to overcome the disadvantages, and new tracers are being developed. In this review, we aim to mention the fundamental components of immunoPET imaging, explore the groundbreaking success achieved using this new technique, and review different radioimmunotracers employed in various solid tumors to elaborate on this relatively new imaging modality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.